Clinical Trial Update: Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid [Phase 1]

View source ↗

Summary

Phase 1 PET ligand trial updates for [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [11C]AZD2184 (AZD2184)
• [11C]AZD2995 (AZD2995)

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer´s Disease | Phase 1 | Status: COMPLETED